Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 13

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 13
---
 Exchange Act of 1934, as amended, or the Exchange Act. In our capacity as a foreign private issuer, we are
exempt from certain rules under the Exchange Act that would otherwise apply if we were a company incorporated in the United States, including:

| · | the requirement to file periodic reports and financial statements with the SEC as frequently or as promptly 
 as United States companies with securities registered under the Exchange Act;                               |

| · | the requirement to file financial statements in accordance with accounting principles generally accepted 
 in the United States, or U.S. GAAP;                                                                      |

| · | the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations; 
 and                                                                                                   |

| · | the requirement to comply with Regulation FD, which imposes certain restrictions on the selective disclosure 
 of material information.                                                                                     |

| 6 |

In addition, our officers,
directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section
16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Ordinary Shares. Accordingly,
an investor may receive less information about us that it would receive about a public company incorporated in the United States.

Additionally, we elect to
follow certain home country corporate governance practices instead of those otherwise required under the listing rules of NASDAQ.

Additional Information

For additional information
related to our business and operations, please refer to the reports incorporated herein by reference, including our Annual Report on Form
20-F for the year ended December 31, 2024, as filed with the SEC on April 11, 2025, and our Reports on Form 6-K, as filed with the SEC,
as described in the section titled “Incorporation of Certain Information by Reference.”

| 7 |

<div align='center'>The Offering</div>

| Issuer                                                                  |     | Biodexa Pharmaceuticals PLC                                                                                                                           |
| Depositary Shares offered by the Selling Shareholder                    |     | Up                                                                                                                                                    
 to 341,352,000,000 Ordinary Shares represented by 34,135,200 Depositary Shares that have been or may be issued by us to the Selling Shareholder       
 pursuant to the Purchase Agreement, including (i) up to 33,413,549 Purchase Shares and (ii) if issued to the Selling Shareholder to release           
 the Company of its liability to pay the Commitment Fee, up to 721,651 Commitment Shares. The actual number of Deposit